PYC Therapeutics Moves Into Final Stage of Child Blindness Study

The Market Herald17:52 ET

PYC Therapeutics Doses First Patient in Blinding Eye Disease Study

MT NewswiresOct 31 20:28 ET

PYC Therapeutics Price Target Raised 9.1% to A$0.24/Share by Canaccord Genuity

Dow JonesOct 22 20:32 ET · Ratings

PYC Therapeutics Replicates Positive Results in Multiple-Dose Phase of Blinding Eye Disease Clinical Trial; Shares Down 8%

MT NewswiresOct 21 21:05 ET

PYC Therapeutics Ltd To Carry Out 1-for-10 Reverse Stock Split On November 15th, 2024

Moomoo NewsOct 14 16:35 ET

PYC Therapeutics Ltd: Annual Report to shareholders

ASXOct 9 02:56 ET · Announcements